150 related articles for article (PubMed ID: 36605847)
1. Massive hyperphosphatemia in clinical tumor lysis syndrome during prophylactic rasburicase use: risk factors and treatment options.
Kikuchi S; Muro M; Kamihara Y; Wada A; Murakami J; Nabe Y; Minemura T; Sato T
Int Cancer Conf J; 2023 Jan; 12(1):69-74. PubMed ID: 36605847
[TBL] [Abstract][Full Text] [Related]
2. Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase.
Alakel N; Middeke JM; Schetelig J; Bornhäuser M
Onco Targets Ther; 2017; 10():597-605. PubMed ID: 28203093
[TBL] [Abstract][Full Text] [Related]
3. Spontaneous Tumor Lysis Syndrome in Blastoid-Variant Mantle Cell Lymphoma: Considerations for the General Internist.
Patel V; Case R
J Investig Med High Impact Case Rep; 2020; 8():2324709620944709. PubMed ID: 32720820
[TBL] [Abstract][Full Text] [Related]
4. Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report.
Galardy PJ; Hochberg J; Perkins SL; Harrison L; Goldman S; Cairo MS
Br J Haematol; 2013 Nov; 163(3):365-72. PubMed ID: 24032600
[TBL] [Abstract][Full Text] [Related]
5. Management of tumor lysis syndrome with a single fixed dose of rasburicase in Asian lymphoma patients: a case series and literature review.
Chiang J; Chan A; Lian T; Tay K; Quek R; Tao M; Lim ST
Asia Pac J Clin Oncol; 2011 Dec; 7(4):351-6. PubMed ID: 22151984
[TBL] [Abstract][Full Text] [Related]
6. Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis.
Lopez-Olivo MA; Pratt G; Palla SL; Salahudeen A
Am J Kidney Dis; 2013 Sep; 62(3):481-92. PubMed ID: 23684124
[TBL] [Abstract][Full Text] [Related]
7. Rasburicase in the management of tumor lysis: an evidence-based review of its place in therapy.
Dinnel J; Moore BL; Skiver BM; Bose P
Core Evid; 2015; 10():23-38. PubMed ID: 25610345
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome.
Jeon YW; Kwak DH; Park SS; Yoon JH; Lee SE; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Min WS; Cho SG
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):595-603. PubMed ID: 28711571
[TBL] [Abstract][Full Text] [Related]
9. Spontaneous Tumor Lysis Syndrome in Diffuse Large B-cell Lymphoma: Early Diagnosis and Management.
Gangireddy M; Shrimanker I; Nookala VK; Peroutka KA
Cureus; 2019 May; 11(5):e4679. PubMed ID: 31328070
[TBL] [Abstract][Full Text] [Related]
10. Tumor Lysis Syndrome.
Barbar T; Jaffer Sathick I
Adv Chronic Kidney Dis; 2021 Sep; 28(5):438-446.e1. PubMed ID: 35190110
[TBL] [Abstract][Full Text] [Related]
11. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
Hummel M; Buchheidt D; Reiter S; Bergmann J; Adam K; Hehlmann R
Eur J Haematol; 2005 Dec; 75(6):518-21. PubMed ID: 16313266
[TBL] [Abstract][Full Text] [Related]
12. A rare case of spontaneous tumor lysis syndrome in multiple myeloma.
Aldabain L; Camire L; Weisman DS
J Community Hosp Intern Med Perspect; 2020 Aug; 10(4):365-368. PubMed ID: 32850100
[TBL] [Abstract][Full Text] [Related]
13. Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma.
Personett HA; Barreto EF; McCullough KB; Dierkhising R; Leung N; Habermann TM
Leuk Lymphoma; 2019 Sep; 60(9):2271-2277. PubMed ID: 31223041
[TBL] [Abstract][Full Text] [Related]
14. Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique.
Darmon M; Vincent F; Camous L; Canet E; Bonmati C; Braun T; Caillot D; Cornillon J; Dimicoli S; Etienne A; Galicier L; Garnier A; Girault S; Hunault-Berger M; Marolleau JP; Moreau P; Raffoux E; Recher C; Thiebaud A; Thieblemont C; Azoulay E;
Br J Haematol; 2013 Aug; 162(4):489-97. PubMed ID: 23772757
[TBL] [Abstract][Full Text] [Related]
15. Acute tumor lysis syndrome in solid tumors--a case report and review of the literature.
Baeksgaard L; Sørensen JB
Cancer Chemother Pharmacol; 2003 Mar; 51(3):187-92. PubMed ID: 12655435
[TBL] [Abstract][Full Text] [Related]
16. Plasma uric acid response to rasburicase: early marker for acute kidney injury in tumor lysis syndrome?
Canet E; Cheminant M; Zafrani L; Thieblemont C; Galicier L; Lengline E; Schnell D; Reuter D; Darmon M; Schlemmer B; Azoulay E
Leuk Lymphoma; 2014 Oct; 55(10):2362-7. PubMed ID: 24325633
[TBL] [Abstract][Full Text] [Related]
17. Tumor lysis syndrome in induction therapy for acute myeloid leukemia before the rasburicase era.
Toda Y; Ashizawa M; Murahashi R; Nakashima H; Ikeda T; Kawaguchi SI; Nagayama T; Umino K; Minakata D; Morita K; Yamamoto C; Hatano K; Sato K; Fujiwara SI; Ohmine K; Kanda Y
Int J Hematol; 2024 Jun; 119(6):660-666. PubMed ID: 38575822
[TBL] [Abstract][Full Text] [Related]
18. Rasburicase for the management of tumor lysis syndrome in neonates.
McNutt DM; Holdsworth MT; Wong C; Hanrahan JD; Winter SS
Ann Pharmacother; 2006; 40(7-8):1445-50. PubMed ID: 16868218
[TBL] [Abstract][Full Text] [Related]
19. Prevention and Treatment of Tumor Lysis Syndrome in the Era of Onco-Nephrology Progress.
Matuszkiewicz-Rowinska J; Malyszko J
Kidney Blood Press Res; 2020; 45(5):645-660. PubMed ID: 32998135
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Single Low-Dose Rasburicase in Management of Tumor Lysis Syndrome in Leukemia and Lymphoma Patients.
Gupta G; Seth T; Garg V; Juneja R; Mahapatra M; Datta SK; Upadhyay AD; Saxena R
Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e99-e104. PubMed ID: 33039358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
